Journal: Microorganisms

Article Title: Hungatella hathewayi : A Tumor-Derived Bacterium Enriched in Colorectal Cancer Tissues and a Potential Diagnostic Biomarker

doi: 10.3390/microorganisms14030707

Figure Lengend Snippet: H. hathewayi -derived succinate upregulates HIF-1α and SUCNR1 expression and promotes metastasis by inducing EMT in HCT15 cells. ( A ) Relative mRNA expression of SUCNR1 in HCT15 cells treated with SA or HHM by qPCR. HCT15 cells were cultured in cell medium with 5% HHM, GAM, and SA (positive control) for 24 h. ( B ) Relative mRNA expression of HIF-1α in HCT15 cells treated with 1 mM SA or HHM by qPCR. Cells were cultured under conditions described in ( A ). Untreated cells served as the blank control. ( C – E ) Relative mRNA expression of CDH1 , Vimentin and Snail1 in HCT15 cells treated with SA or HHM by qPCR. Cells were cultured under conditions described in ( A ). Untreated cells served as the blank control. ( F ) Analysis of CDH1, HIF-1α, Snail1, and Vimentin protein expression in HCT15 cells by Western blot. HCT15 cells were cultured in cell medium with 5% HHM, GAM, and SA (positive control) for 24 h. HHM, the culture medium supernatant of H. hathewayi . GAM, bacterial culture medium. SA, 1 mM succinate. Data were from independent experiments and shown as mean ± SD. Compared using Student’s t -test between two groups, and differences among the groups were calculated using One Way ANOVA, followed by Dunnett’s multiple comparison test. Differences among the groups were calculated using One Way ANOVA. * p < 0.05, ** p < 0.01 and **** p < 0.0001.

Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies targeting NLRP3 (Cat No. 30109-1-AP, ProteinTech Group, Inc., Rosemont, IL, USA), IL-1β (516288, ZEN-BIOSCIENCE Co., Ltd., Chengdu, China), ASC (Cat No. 10500-1-AP, ProteinTech Group, Inc.), Caspase-1 (Cat No. 22915-1-AP, ProteinTech Group, Inc.), IL-18 (Cat No. 10663-1-AP, ProteinTech Group, Inc.), HIF-1α (Cat. PB9253, Boster Biological Technology Co., Ltd., Wuhan, China), CDH1 (Cat. PTM-6222, PTM BioLab Inc., Hangzhou, China), Vimentin (Cat. PTM-5376, PTM BioLab Inc.), Snail1 (Cat. 3879, Cell Signaling Technology, Inc., Danvers, MA, USA), and β-actin (Cat. PTM-5455, PTM BioLab Inc.), followed by a 1 h incubation with secondary antibodies (Cat No. SA00001-2, ProteinTech Group, Inc.) at room temperature.

Techniques: Derivative Assay, Expressing, Cell Culture, Positive Control, Control, Western Blot, Comparison

Journal: Frontiers in Immunology

Article Title: Integrating chronic inflammation and hypoxia: the potential role of HIF-1α in tumor behavior and therapy response in high-grade serous ovarian cancer

doi: 10.3389/fimmu.2026.1757708

Figure Lengend Snippet: (A) mRNA expression of HIF-1α in ovary (n=26) and omentum (n=21). (B) mRNA expression of HIF-1α in peritoneum at PS (n=23) and IDS (n=20). (C) Concentration of HIF-1α in ascites at PS (n=28), plasma at PS (n=28) and plasma at IDS (n=20). HGSOC, High-grade serous ovarian cancer; ACT, adjuvant chemotherapy; NACT, neoadjuvant chemotherapy; PS, primary surgery; IDS, interval debulking surgery; HIF-1α, Hypoxia-inducible factor 1-alpha.

Article Snippet: HIF-1α concentrations in ascites and plasma were quantified using a Human HIF-1α ELISA kit (CSB-E12112h, CUSABIO, Wuhan, China) following the manufacturer’s instructions.

Techniques: Expressing, Concentration Assay, Clinical Proteomics, Adjuvant

Journal: Frontiers in Immunology

Article Title: Integrating chronic inflammation and hypoxia: the potential role of HIF-1α in tumor behavior and therapy response in high-grade serous ovarian cancer

doi: 10.3389/fimmu.2026.1757708

Figure Lengend Snippet: (A) Concentration of HIF-1α in ascites at PS grouped by ESR (ESR ≤30 mm/h, n=5; ESR >30 mm/h, n=23). (B) Concentration of HIF-1α in plasma at PS grouped by ESR (ESR ≤30 mm/h, n=5; ESR >30 mm/h, n=23). (C) Concentration of HIF-1α in ascites at PS grouped by CRS (CRS 1, n=11; CRS 2, n=7; CRS 3, n=5). (D) Concentration of HIF-1α in plasma at PS grouped by CRS (CRS 1, n=11; CRS 2, n=7; CRS 3, n=5). PS, primary surgery; IDS, interval debulking surgery; ESR, erythrocyte sedimentation rate; CRS, chemotherapy response score; HIF-1α, Hypoxia-inducible factor 1-alpha.

Article Snippet: HIF-1α concentrations in ascites and plasma were quantified using a Human HIF-1α ELISA kit (CSB-E12112h, CUSABIO, Wuhan, China) following the manufacturer’s instructions.

Techniques: Concentration Assay, Clinical Proteomics, Sedimentation

Journal: Frontiers in Immunology

Article Title: Integrating chronic inflammation and hypoxia: the potential role of HIF-1α in tumor behavior and therapy response in high-grade serous ovarian cancer

doi: 10.3389/fimmu.2026.1757708

Figure Lengend Snippet: (A) mRNA expression of HIF-1α in peritoneum at PS stratified by PFS (PFS ≤30, n=17; PFS >30, n=6). (B) Kaplan-Meier survival curve of PFS according to peritoneal HIF-1α mRNA expression. HIF-1α low: peritoneal HIF-1α mRNA expression at PS is below optimal cutoff of 0.01124, n=17; HIF-1α high: peritoneal HIF-1α mRNA expression at PS is above optimal cutoff of 0.01124, n=6. (C) Kaplan-Meier survival curve of PFI according to peritoneal HIF-1α mRNA expression. HIF-1α low: peritoneal HIF-1α mRNA expression at PS is below median of 0.01124, n=9; HIF-1α high: peritoneal HIF-1α mRNA expression at PS is above median of 0.01124, n=11. PFS, progression free survival; PFI, platinum free interval; PS, primary surgery; HIF-1α, Hypoxia-inducible factor 1-alpha.

Article Snippet: HIF-1α concentrations in ascites and plasma were quantified using a Human HIF-1α ELISA kit (CSB-E12112h, CUSABIO, Wuhan, China) following the manufacturer’s instructions.

Techniques: Expressing